Trial · NCT01284348
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Experienced a Hematopoietic Response | Sotatercept 15 mg | 2 | Participants | ||
| Number of Participants Who Experienced a Hematopoietic Response | Sotatercept 30 mg | 2 | Participants | ||
| Number of Participants Who Experienced One or More Adverse Events (AEs) | Sotatercept 15 mg | 14 | Participants | ||
| Number of Participants Who Experienced One or More Adverse Events (AEs) | Sotatercept 30 mg | 10 | Participants | ||
| Area Under the Concentration Versus Time Curve From Time 0 to 28 Days (AUC0-28d) of Sotatercept Following a Single Dose | Sotatercept 15 mg | 24443.28 | Standard Deviation 8130.52 | day*ng/mL | |
| Area Under the Concentration Versus Time Curve From Time 0 to 28 Days (AUC0-28d) of Sotatercept Following a Single Dose | Sotatercept 30 mg | 43977.03 | Standard Deviation 18490.17 | day*ng/mL | |
| Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC0-inf) of Sotatercept Following a Single Dose | Sotatercept 15 mg | 40145.34 | Standard Deviation 20680.76 | day*ng/mL | |
| Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC0-inf) of Sotatercept Following a Single Dose | Sotatercept 30 mg | 137994.6 | Standard Deviation 18183.66 | day*ng/mL | |
| Maximum Plasma Concentration (Cmax) of Sotatercept Following a Single Dose | Sotatercept 15 mg | 1325.33 | Standard Deviation 435.89 | ng/mL | |
| Maximum Plasma Concentration (Cmax) of Sotatercept Following a Single Dose | Sotatercept 30 mg | 2069.68 | Standard Deviation 842.43 | ng/mL | |
| Time to Maximum Concetration (Tmax) of Sotatercept Following a Single Dose | Sotatercept 15 mg | 8.16 | Standard Deviation 3.78 | Days | |
| Time to Maximum Concetration (Tmax) of Sotatercept Following a Single Dose | Sotatercept 30 mg | 12.31 | Standard Deviation 7.67 | Days | |
| Apparent Terminal Half-life (t1/2) of Sotatercept Following a Single Dose | Sotatercept 15 mg | 18.98 | Standard Deviation 7.96 | Days | |
| Apparent Terminal Half-life (t1/2) of Sotatercept Following a Single Dose | Sotatercept 30 mg | 30.84 | Standard Deviation 9.46 | Days | |
| Apparent Serum Clearance (CL/F) of Sotatercept Following a Single Dose | Sotatercept 15 mg | 479.36 | Standard Deviation 254.44 | mL/day | |
| Apparent Serum Clearance (CL/F) of Sotatercept Following a Single Dose | Sotatercept 30 mg | 220.14 | Standard Deviation 31.17 | mL/day | |
| Apparent Volume of Distribution (Vz/F) Following a Single Dose of Sotatercept | Sotatercept 15 mg | 11944.60 | Standard Deviation 7172.84 | mL | |
| Apparent Volume of Distribution (Vz/F) Following a Single Dose of Sotatercept | Sotatercept 30 mg | 9849.80 | Standard Deviation 3449.33 | mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01284348/results